Profiel
Dr. Mythili Koneru was previously employed as a Chief Medical Officer by Legend Biotech Corp., a Chief Medical Officer by Marker Therapeutics, Inc., and an Associate Vice President-Immuno-Oncology by Eli Lilly & Co. She received her undergraduate degree from The University of Chicago, a doctorate degree from New York University and a doctorate degree from Robert Wood Johnson Medical School.
Eerdere bekende functies van Mythili Koneru
| Bedrijven | Functie | Einde |
|---|---|---|
| LEGEND BIOTECH CORPORATION | Hoofd Techniek/Wetenschap/O&O | 01-10-2025 |
| MARKER THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 09-04-2023 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01-02-2019 |
Opleiding van Mythili Koneru
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 6 |
|---|---|
Eli Lilly & Co.
Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
Marker Therapeutics, Inc.
Marker Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes cell based immune therapeutics and vaccines for cancer treatment | Health Technology |
The University of Chicago
The University of Chicago Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
New York University
New York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Robert Wood Johnson Medical School
Robert Wood Johnson Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Legend Biotech Corp.
Legend Biotech Corp. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biopharmaceutical company which engages in the discovery and development of novel cell therapies for oncology | Health Technology |
















